5.1. General Results for Adults
All models are estimated with the NLOGIT 4.0 software by the random parameter logit model using 1,000 repetitions for simulated probabilities with Halton draws. We specify the PRICE, ASC_SQ and all variables with cross-terms as fixed parameters. The RISK, DATE, LUNG, CANCER and TRAFFIC coefficients are allowed to vary and are assumed to be normally distributed. The estimated results for Model 1 are presented in
Table 5 for each city and the pooled data.
Table 5.
Estimated Results for Model 1.
Table 5.
Estimated Results for Model 1.
| Model 1 |
---|
Mean Parameters | Afsin-Elbistan | Kutahya-Tavsanli | Ankara | Pooled |
---|
RISK | 0.518 | *** | 0.577 | *** | 0.403 | *** | 0.556 | *** |
| (0.152) | | (0.222) | | (0.124) | | (0.103) | |
DATE | −2.851 | *** | −5.553 | *** | −2.723 | *** | −3.669 | *** |
| (0.586) | | (1.198) | | (0.571) | | (0.453) | |
LUNG | 2.561 | *** | 4.439 | *** | 3.850 | *** | 3.315 | *** |
| (0.560) | | (1.164) | | (0.859) | | (0.443) | |
CANCER | 1.236 | *** | 1.528 | ** | 2.522 | *** | 1.807 | *** |
| (0.464) | | (0.771) | | (0.652) | | (0.366) | |
TRAFFIC | −4.399 | *** | −10.748 | *** | −2.465 | *** | −5.653 | *** |
| (1.121) | | (2.601) | | (0.837) | | (0.893) | |
Fixed Parameters |
ASC_SQ | −5.691 | *** | −9.308 | *** | −5.158 | *** | −6.590 | *** |
| (0.991) | | (1.939) | | (1.046) | | (0.713) | |
PRICE | −0.006 | *** | −0.011 | *** | −0.006 | *** | −0.008 | *** |
| (0.001) | | (0.002) | | (0.001) | | (0.001) | |
Standard Deviation Parameters |
RISK | 1.316 | *** | 3.096 | *** | 1.056 | *** | 1.735 | *** |
| (0.249) | | (0.661) | | (0.212) | | (0.196) | |
DATE | 2.484 | *** | 3.563 | *** | 2.085 | *** | 2.604 | *** |
| (0.618) | | (1.078) | | (0.537) | | (0.408) | |
LUNG | 2.415 | *** | 3.404 | *** | 3.093 | *** | 2.886 | *** |
| (0.844) | | (1.143) | | (0.985) | | (0.623) | |
CANCER | 3.800 | *** | 9.195 | *** | 3.777 | *** | 5.459 | *** |
| (1.068) | | (2.468) | | (0.981) | | (0.832) | |
TRAFFIC | 6.940 | *** | 13.767 | *** | 5.280 | *** | 8.640 | *** |
| (1.666) | | (3.306) | | (1.279) | | (1.256) | |
Log likelihood | −995 | | −955 | | −620 | | −2609 | |
McFaaden Pseudo R2 | 0.29 | | 0.33 | | 0.34 | | 0.31 | |
Number of Observations | 1283 | | 1305 | | 850 | | 3438 | |
In Model 1, all variables are statistically significant at least at the five percent level. All statistically significant estimates are with expected signs, i.e., negative for PRICE and DATE, positive for RISK, indicating the preferences for lower price, earlier and higher risk reductions. The statistically significant estimates for standard deviation parameters indicate that these parameters actually vary in the population. The variables for the causes of premature mortalities, LUNG (lung cancer) and CANCER (other cancer) are positive, while TRAFFIC is negative and significant. The base line risk type is the respiratory disease. This result suggests that the WTPs for reducing risk caused by the lung cancer or other type of cancer are higher (regardless of the amount of risk reduction) than the respiratory disease case and is lower than the traffic accident. Furthermore, it is revealed that different amount of premiums are given to different types of cancers. The ranking of the premiums (1. lung cancer, 2. other type of cancer, 3. respiratory diseases, 4. traffic accident) coincides in all three cities.
When we compare the results across the cities, the different characteristics observed for Kutahya-Tavsanli become clear. Risk reduction is evaluated the most and postponed risk reduction for one year (DATE) is devaluated the most in Kutahya-Tavsanli. However, the respondents in Kutahya-Tavsanli are more sensitive to the price of the risk reduction package. As a result, when we calculate the willingness to pay for 1 in 10,000 risk reduction and the value of statistical life, the results for Kutahya-Tavsanli are recorded as the lowest. Here, we observe the discrepancy between the risk perception and willingness (capability) for payment. This tendency could also be observed from the difference in the out-of-pocket monthly medical costs for chronic illnesses in these cities. The average monthly out-of-pocket medical cost is 72 TL (maximum 7500 TL) in Afsin-Elbistan while it is 40 TL (maximum 3000 TL) in Kutahya-Tavsanli in our sample. Kutahya-Tavsanli respondents care about the differences of the causes of the mortality risk reductions the most as well.
The alternative specific constants for the status quo (ASC_SQ, coded as 1 for status-quo and 0 otherwise) are negative and significant for all models. This implies the disutility against the status-quo or the no-risk reduction situation. Such disutility is the highest in Kutahya-Tavsanli and the lowest in Ankara. The PRICE variable is also negative and statistically significant as expected, meaning an increase in the price of the mortality risk reduction decreases the probability of an alternative profile to be chosen as oppose to the status quo.
The point estimates of marginal WTP and the estimated VSL are reported in
Table 6, based on the estimated results of Model 1 and using the TL-USD exchange rate as of July 2nd, 2012 (1 USD = 1.80 TL) and the purchasing power parity (PPP) of TL × 1.189 by using the 2011 PPP values reported in the OECD.StatExtracts database [
23]. The standard errors are estimated by using 10,000 repetitions of the Krinsky and Robb method [
24]. The values of 1 in 10,000 reduction of mortality risk are calculated as 85 TL ($47), 53 TL ($29), and 69 TL ($38) for Afsin-Elbistan, Kutahya-Tavsanli, and Ankara, respectively. Although the risk reduction is evaluated the highest in Kutahya-Tavsanli, due to the price sensitivity, the calculated MWTP for 1 in 10,000 risk reduction becomes the lowest among three cities. The risk reduction that will start after one year decreases the WTP by 471 TL ($262), 508 TL ($282), and 466 TL ($259) for Afsin-Elbistan, Kutahya-Tavsanli and Ankara, respectively, compared to the immediate risk reduction. This result suggests that the discount rate for the risk reduction is the highest in Kutahya-Tavsanli and the lowest in Ankara. Although we cannot compare the magnitudes of cancer premiums directly across different cities since the LUNG, CANCER and TRAFFIC variables are dummy variables, we confirmed that people evaluate distinctive types of risk reduction differently regardless of the reduction amount. This is further investigated with Model 2 in the following section. Compared to the alternatives, the status quo option (no reduction in premature mortality risk) is associated with the lower level of utility, and the difference is found to be 940 TL ($522), 851 TL ($473), and 883 TL ($491) in Afsin-Elbistan, Kutahya-Tavsanli and Ankara, respectively. As in the case for RISK estimate, although respondents in Kutahya-Tavsanli seek for the risk reduction alternatives the most, its WTP is estimated the lowest among others due to their price sensitivity. Although transfers of WTP estimates to other parts of Turkey have to be done through well-examined benefits transfers, if we focus on the relationship between the national and sample income distributions, the WTP estimates for Afsin-Elbistan and Kutahya-Tavsanli could be good representatives for the rural areas and the national average, respectively. The WTP for Ankara might be overestimated for urban population. However, as the WTP values for Afsin-Elbistan are higher than the ones in Kutahya-Tavsanli where the income level is higher, it is difficult to generalize our estimates to other areas without taking into account other major factors such as the baseline health and environmental risks.
Table 6.
Point Estimates for Marginal WTP and Estimated VSL based on Model 1 (TL).
Table 6.
Point Estimates for Marginal WTP and Estimated VSL based on Model 1 (TL).
Variable | Afsin-Elbistan | Kutahya-Tavsanli | Ankara | Pooled |
---|
| WTP | S.E. | WTP | S.E. | WTP | S.E. | WTP | S.E. |
RISK | 85 | 21 | 53 | 19 | 69 | 21 | 74 | 12 |
DATE | −471 | 70 | −508 | 65 | −466 | −87 | −489 | 38 |
LUNG | 423 | 94 | 406 | 85 | 659 | 188 | 441 | 51 |
CANCER | 204 | 89 | 140 | 82 | 432 | 126 | 241 | 48 |
TRAFFIC | −726 | 173 | −983 | 196 | −422 | 147 | −753 | 103 |
ASC_SQ | −940 | 74 | −851 | 44 | −883 | 81 | −877 | 31 |
VSL (TL) | 854,420 | 527,878 | 689,104 | 740,838 |
VSL(PPP,$) | 564,392 | 348,692 | 455,191 | 489,364 |
As for the derived VSL, the highest VSL is for the Afsin-Elbistan sample while the lowest is for Kutahya-Tavsanli. As we have discussed earlier, there are two factors affecting the magnitudes of VSL. One is the level of premature mortality risk perception and the other is willingness and capacity to pay for risk reduction. If we use the result from pooled data as the average VSL in these three cities in Turkey, 740,838 TL (489,364 PPP adjusted USD), about half a million dollars is the VSL value we have estimated for Turkey.
Although our estimated VSL is higher than the VSL estimated in developing countries such as in China ($4000–$17,000 in 1999 USD [
4], $34,458 in 1998 USD [
11]) and India ($150,000, PPP adjusted 2005 USD, [
10]), it is significantly lower than the estimates for developed countries such as $7.4 million (in 2006 USD), the recommended value by the U.S. Environmental Protection Agency for USA [
6] and $ 2.9 million in 2002 USD for Japan estimated by Tsuge
et al. [
17]. Our estimate is slightly more than one-fourth of the value adopted by the European Environment Agency (EEA), that is 1.4 million Euro in 2000 Euros (approximately $1.34 million in 2000 USD or $1.72 million in 2012 USD) [
7]. It is a half of the middle value of VSL estimates using income-elasticity adjustment ($0.6 million (in 1989 USD) = $0.98 million (in 2012 USD)) and very close to the middle value of VSL estimates using wage-rate adjustment ($0.29 million (in 1989 USD) = $0.47 million (in 2012 USD)) for Central and Eastern Europe derived by Krupnick
et al. [
25] based on benefits transfer using US, Canada and Western European studies. Other studies that estimated a similar VSL as our study are the one for Mongolia ($0.49 million in PPP adjusted 2009 USD, [
9]) and the wage-based estimates for Taiwan, $0.4 and $0.6 million in the late 90s [
26,
27].
Model 2 is intended to reveal the “Cancer Risk Premium” (
Table 7). Here, we define the cancer risk premium as the summation of two factors, (i) WTP for the opportunity of reducing the cancer risk (regardless of the degree of risk reduction) and (ii) WTP for reducing the cancer risk per one unit (1/10,000 in our case) of mortality risk reduction [
15]. Therefore, the total cancer risk premium that is defined as the difference from the base risk case (respiratory disease) can be calculated as follows:
where
k corresponds to risk types, LUNG or CANCER, and
ΒK_RISK are the coefficients of risk type-risk cross terms (RESP is the base risk type). The first term does not rely on the amount of risk reduction while the second term is the WTP per unit reduction of the mortality risk. For example, the premium for the general cancer risk for Afsin-Elbistan is calculated as
. The difference between the mortality risk reduction from respiratory illness and from traffic accident is also calculated by setting −β
k as −β
Traffic and β
k_RISK as β
Traffic_RISK. The premium for the larger risk reduction should be calculated as the first term plus the second term multiplied by the size of the risk reduction. The calculated premiums by taking RESP as the base risk type is reported in
Table 8.
The premiums are positive for both lung cancer and the other type of cancer. The negative calculated “Premium” for traffic accident indicates the respondents’ stronger preference for reducing the mortality risk from respiratory illnesses compared to the traffic accident. Distribution of risk-risk trade-offs between the risk of contracting chronic bronchitis (CB) and auto fatality reported in Viscusi
et al. [
28] shows that for the median respondent, the auto death risk was three times more highly valued than the CB risk while the top 20% of the distribution of trade-offs revealed that CB was more highly (up to four times) valued than traffic fatality. Since our study considers mortalities from both risks, we cannot compare the results directly. However, it seems that our respondents value the mortality risks between respiratory illnesses (including CB) and traffic accidents quite differently from their study.
Since we did not provide detailed description of each risk type, respondents’ answers were based on their perceived mortality risks from each risk type. One of the follow-up questions (“The mortality risk of the following risk type is high, do you agree?”) reveals individuals’ perceptions on mortality risks (
Table 3). The perceived mortality risk is the highest for Lung Cancer, followed by Traffic Accident and Other Type of Cancer. The calculated differences in the WTP values and the perceived mortality risk for each risk type reveals that the WTP is not solely determined by the level of perceived mortality risk, but also with other factors such as pain, fear, and the duration of suffering. The result shows that our respondents gave a higher weight for non-mortality aspects of respiratory illnesses. The calculated cancer premium for lung cancer is 213% on average, and it is 597% for other types of cancer.
Although there is no study estimating the cancer premium in developing countries, to the best of our knowledge, if we compare our results from the cancer premium estimates for developed countries that range from no premium to 200% premium, it seems quite high. In UK, the cancer premium of 100% is recommended [
29] and in the US, it is 50% for their policy assessments [
30]. Magat
et al. [
31] found a 58% premium for curable lymph cancer against automobile accident deaths at the mean values, Viscusi
et al. [
32] estimated the cancer premium for fatal bladder cancer from drinking arsenic contaminated water and found a 21% premium compared to the US estimates for acute accidents using a large US sample, and Van Houtven
et al. [
33] found a 200% premium for cancer ($19 million) against immediate fatal accidents ($6 million) when the latency period was 5 years in the US. Hammitt and Liu [
34] found a 30% premium for lung or liver cancer compared to the non-cancer lung or liver diseases in Taiwan, while Hammitt and Haninger [
35] found no premium in the US.
The extremely high premium for the general (non-lung) cancer risk is highly likely due to the generality of the “cancer” definition. According to the subjective risk perceptions reported in
Table 3, “Other Type of Cancer” earned the lowest percentages of agreement for all four questions, the lowest perceived mortality risk, the lowest personal responsibility, the lowest private knowledge and the lowest responsibility of public policy for all three study areas. This is an indication of the variations in the respondents-defined risk type and it is also possible that some respondents consider multiple types of cancer risks at the same time. In addition, people tend to over-estimate the risk when they are not familiar with it. This result brings us to the conclusion that “cancer risk premiums” have to be determined based on a specific type of cancer, not as general cancer. Therefore, we conclude that 213% of lung cancer premium is a more reliable estimate than the general cancer premium in our study.
Table 7.
Estimated Result and Risk Type Premium for Model 2.
Table 7.
Estimated Result and Risk Type Premium for Model 2.
| Model 2 |
---|
Mean Parameters | Afsin-Elbistan | Kutahya-Tavsanli | Ankara | Pooled |
---|
RISK | 0.999 | *** | 1.156 | *** | 1.700 | *** | 1.330 | *** |
| (0.322) | | (0.337) | | (0.609) | | (0.288) | |
DATE | −3.732 | *** | −6.913 | *** | −6.427 | *** | −5.252 | *** |
| (0.920) | | (1.061) | | (2.011) | | (0.841) | |
LUNG | −2.800 | | −5.673 | | −3.736 | | −4.222 | ** |
| (2.032) | | (4.423) | | (4.279) | | (1.683) | |
CANCER | 7.101 | *** | 7.680 | *** | 12.833 | *** | 8.486 | *** |
| (2.087) | | (2.594) | | (4.567) | | (1.720) | |
TRAFFIC | −6.027 | *** | −9.383 | *** | 0.126 | | −5.655 | *** |
| (1.998) | | (2.655) | | (1.976) | | (1.368) | |
Fixed Parameters |
ASC_SQ | −5.562 | *** | −7.355 | *** | −6.441 | *** | −6.210 | *** |
| (1.179) | | (2.047) | | (2.103) | | (0.889) | |
PRICE | −0.006 | *** | −0.009 | *** | −0.008 | *** | −0.008 | *** |
| (0.002) | | (0.003) | | (0.003) | | (0.001) | |
LUNG*RISK | 1.906 | *** | 2.898 | ** | 3.339 | ** | 2.569 | *** |
| (0.714) | | (1.345) | | (1.648) | | (0.610) | |
CANCER*RISK | −1.323 | *** | −1.470 | *** | −1.797 | ** | −1.455 | *** |
| (0.413) | | (0.479) | | (0.747) | | (0.334) | |
TRAF*RISK | 0.090 | | −0.686 | ** | −0.806 | * | −0.295 | * |
| (0.205) | | (0.298) | | (0.425) | | (0.167) | |
Log likelihood | −979 | | −940 | | −605 | | −2568 | |
McFaaden Pseudo | 0.31 | | 0.34 | | 0.35 | | 0.32 | |
Number of Obs. | 1283 | | 1305 | | 850 | | 3438 | |
Table 8.
Differences in WTP for Different Risk Types (TL) *.
Table 8.
Differences in WTP for Different Risk Types (TL) *.
Risk Type | Afsin-Elbistan | Kutahya-Tavsanli | Ankara | Average |
---|
LUNG | 314 | 320 | 399 | 344 |
CANCER | 952 | 685 | 1317 | 985 |
TRAFFIC | −993 | −1110 | −96 | −733 |
5.3. Age, Status-Quo Preference and Risk Valuation
Given the insignificant age effects on the valuation of risk reduction confirmed in Model 4 and 6 for Afsin-Elbistan and Ankara, Model 7 and Model 8 with multiple age group dummy variables are tested to further examine the underlying age-status-quo preference and age-risk valuation relationship (
Table 11). The findings in the existing studies regarding age-risk valuation (VSL) are mixed [
13,
16,
37,
38]. By observing the estimates from multiple trials based on Model 7, we identified the “peak” (all the other estimates have negative signs) of the coefficients among other age groups and dropped the identified age group as the baseline of the age dummy variables. The estimated results of Model 7 indicate that the older age groups (60–64 and 65–75 in Afsin-Elbistan, 55–59, 60–64 and 65–75 in Kutahya-Tavsanli, and 55–59 and 60–64 in Ankara) are confirmed to have statistically significantly lower valuation for risk reduction than their base age-groups (30–34 for Afsin-Elbistan and Kutahya-Tavsanli, and 35–39 for Ankara). In other words, we have confirmed the differences in risk preference between 54 and younger and older age groups.
Furthermore, the calculated VSL values based on Model 7 are revealed to be negative for age groups 55–59, 60–64 and 65–75 in Kutahya and 55–59 and 60–64 in Ankara. Negative WTP could be interpreted as 1 in 10,000 risk reduction policy is “bad”, not “good” for this age group. One of the possible reasons for this low or negative WTP value could stem from the existing “status-quo bias” among seniors [
39,
40].
In order to test the status-quo bias among seniors, we included three status-quo cross terms with elderly age dummies (55–59, 60–64 and 65–75) in Model 8 in addition to the variables in Model 7. This model is intended to separate the status-quo preference from risk evaluation for senior age groups. The result of the model reveals the disappearance of, or weakened senior discount effect after separating the preference for the status-quo option for the Kutahya-Tavsanli and Ankara case, but not for the Afsin-Elbistan case. The possible causes of “senior discount” could vary, but the stronger preference for the status-quo option among elderly seems to be one of the reasons. As for Kutahya-Tavsanli, no RISK cross terms are statistically significant and AGE6575 × ASC_SQ is positive significant at the one percent level. As for Ankara, AGE6064 × ASC_SQ and AGE6575 × ASC_SQ are statistically significant at the 1% and 10% levels, respectively, indicating the status-quo preference. The signs of AGE5559 × ASC_SQ are all negative and AGE6064 × ASC_SQ and AGE6575 × ASC_SQ are all positive for all locations. This result shows clear changes in the status-quo preference around age sixty. When we separate the status-quo preference from risk valuation, the “senior discount” disappeared (statistically insignificant risk cross terms for AGE5559, AGE6064 and AGE6575 from the Kutahya-Tavsanli and AGE6064 from the Ankara cases). As a result, the corresponding VSL for the relevant age groups became higher. According to
Table 12, the VSL values for all age groups are statistically indifferent from VSL for their base age group (30–34 for Kutahya-Tavsanli and 35–39 for Ankara), except for the 55–59 age group in Ankara.
Table 11.
Estimated Result of Age Models—Model 7 and Model 8.
Table 11.
Estimated Result of Age Models—Model 7 and Model 8.
| Model 7 | Model 8 |
---|
Mean Parameters | Afsin-Elbistan | Kutahya-Tavsanli | Ankara | Afsin-Elbistan | Kutahya-Tavsanli | Ankara |
---|
RISK | 1.029 | *** | 1.521 | ** | 0.842 | *** | 1.057 | *** | 1.494 | ** | 0.703 | ** |
| (0.294) | | (0.626) | | (0.315) | | (0.312) | | (0.715) | | (0.299) | |
DATE | −2.926 | *** | −5.973 | *** | −2.950 | *** | −3.039 | *** | −7.260 | *** | −2.767 | *** |
| (0.591) | | (1.226) | | (0.696) | | (0.647) | | (1.765) | | (0.659) | |
LUNG | 2.687 | *** | 4.838 | *** | 4.286 | *** | 2.806 | *** | 5.799 | *** | 4.074 | *** |
| (0.599) | | (1.154) | | (1.101) | | (0.659) | | (1.715) | | (1.037) | |
CANCER | 1.243 | *** | 1.316 | | 2.666 | *** | 1.287 | ** | 1.881 | | 2.474 | *** |
| (0.467) | | (0.860) | | (0.768) | | (0.495) | | (1.190) | | (0.721) | |
TRAFFIC | −4.564 | *** | −11.980 | *** | −2.446 | *** | −4.762 | *** | −13.600 | *** | −2.315 | *** |
| (1.160) | | (2.828) | | (0.874) | | (1.258) | | (3.529) | | (0.815) | |
Fixed Parameters | | | | | | | | | | | | |
ASC_SQ | −6.015 | *** | −9.567 | *** | −5.492 | *** | −6.229 | *** | −11.600 | *** | −5.802 | *** |
| (1.072) | | (1.987) | | (1.232) | | (1.166) | | (2.903) | | (1.273) | |
PRICE | −0.007 | *** | −0.011 | *** | −0.006 | *** | −0.007 | *** | −0.010 | *** | −0.006 | *** |
| (0.001) | | (0.003) | | (0.002) | | (0.001) | | (0.004) | | (0.002) | |
Cross Terms with ASC_SQ |
AGE5559 | | | | | | | −1.003 | | −2.610 | | −0.616 | |
| | | | | | | (1.631) | | (2.199) | | (1.166) | |
AGE6064 | | | | | | | 0.950 | | 0.363 | | 7.225 | *** |
| | | | | | | (0.871) | | (2.510) | | (2.277) | |
AGE6575 | | | | | | | 0.181 | | 8.500 | *** | 2.508 | ** |
| | | | | | | (1.100) | | (2.824) | | (1.186) | |
Cross Terms with RISK |
AGE1824 | −0.513 | | −0.311 | | −0.436 | | −0.531 | | −0.080 | | −0.405 | |
| (0.363) | | (0.773) | | (0.444) | | (0.375) | | (1.106) | | (0.422) | |
AGE2529 | −0.504 | * | −1.155 | | −0.042 | | −0.518 | | −0.650 | | −0.028 | |
| (0.291) | | (0.747) | | (0.371) | | (0.301) | | (1.019) | | (0.348) | |
AGE3034 | | | | | −0.451 | | | | | | −0.418 | |
| | | | | (0.346) | | | | | | (0.337) | |
AGE3539 | −0.578 | * | −0.672 | | | | −0.599 | * | −0.730 | | | |
| (0.321) | | (0.763) | | | | (0.335) | | (0.883) | | | |
AGE4044 | −0.489 | | −0.371 | | −0.135 | | −0.499 | | 0.341 | | −0.103 | |
| (0.317) | | (0.729) | | (0.351) | | (0.326) | | (0.864) | | (0.334) | |
AGE4549 | −0.666 | ** | −0.568 | | −0.188 | | −0.688 | ** | −0.740 | | −0.158 | |
| (0.320) | | (0.798) | | (0.342) | | (0.335) | | (0.963) | | (0.328) | |
AGE5054 | −0.657 | * | −0.831 | | −0.206 | | −0.681 | * | −0.700 | | −0.173 | |
| (0.376) | | (0.764) | | (0.333) | | (0.402) | | (0.922) | | (0.327) | |
AGE5559 | −0.374 | | −1.524 | * | −1.157 | ** | −0.541 | | −1.970 | | −1.218 | ** |
| (0.437) | | (0.885) | | (0.511) | | (0.513) | | (1.239) | | (0.531) | |
AGE6064 | −0.642 | * | −1.700 | ** | −1.665 | *** | −0.543 | | −1.170 | | −0.097 | |
| (0.350) | | (0.855) | | (0.604) | | (0.370) | | (1.327) | | (0.529) | |
AGE6575 | −0.971 | ** | −3.187 | *** | −0.537 | | −0.975 | * | −1.700 | | −0.089 | |
| (0.449) | | (0.836) | | (0.450) | | (0.507) | | (1.261) | | (0.482) | |
Log L | −991 | | −946 | | −610 | | −990 | | −935 | | −596 | |
PseudoR2 | 0.3 | | 0.34 | | 0.35 | | 0.3 | | 0.35 | | 0.36 | |
N. of Obs. | 1283 | | 1305 | | 850 | | 1283 | | 1305 | | 850 | |
The VSL for the 55–59 age group is calculated based on the coefficient statistically significant at five percent level as −895,647. We have checked for outliers and outstanding characteristics of each observation in this age group, but did not find anything abnormal. Different model specifications have also been tried, but statistically significant AGE5559 × RISK terms were always found. This unexpected result may stem from the fact that the percentage of respondents who are not working, including housewives and retired, increases significantly from 49% for 50–54 to 84% for the 55–59 age group, and as a result, the average household income decreases from 2932 TL to 2232 TL between these two age groups. Since the retirement age is 60 in Turkey, a remarkable increase in the “not-working” proportion of the 55–59 age group is due to the individuals who decided to retire early. We imagine that this age group is in a transition phase from being labor force, to being not-in-labor-force and people may be under the influence of a “significant income loss” and in a psychological stage of “adjusting the reference point” [
41]. Observing the fact that the average household income for 60–64 and 65–75 are even lower (2156 TL, 2076 TL) but with no unexpected pattern, it is possible that there is psychological difference between 60 and above (retired at normal retirement age) and 55–59 (could have worked some more years, but decided to retire early, therefore experienced “income loss” by own decision). Although it is not statistically significant, we observe negative VSL for the 55–59 age group for Kutahya-Tavsanli. However, the difference between the average household income before 55 and 55–59 is not as notable for Kutahya-Tavsanli (around 250 TL) as for Ankara (more than 600 TL). As for Afsin-Elbistan, because of the small difference between the average household income before 55 and 55–59 (approximately 300 TL) and the high background health risk condition, we do not observe the same pattern.
As for Afsin-Elbistan, none of the status-quo cross terms have sufficient explanatory power for this case. This fact could be related to the strong desire among the residents for the policy change regarding air pollution in the area. the VSL for 30–34 age group is 1,592,593 TL while it decreases to 556,424 TL for the 45–49 age group and 123,498 TL for the 65–75 age group. The VSL for the 65–75 age group is approximately one tenth of the peak VSL at the 30–34 age group. This confirms the existence of “senior discount” in this case. However, the amount of discount became smaller once the status-quo bias was removed.
Table 12.
Estimated VSL from Model 8 (in TL).
Table 12.
Estimated VSL from Model 8 (in TL).
Age Groups | Afsin-Elbistan | Kutahya-Tavsanli | Ankara |
---|
18–24 | 792,120 | 1,059,927 | 518.806 |
25–29 | 812,626 | 634,545 | 1,173,728 |
30–34 | 1,592,593 * | 1,122,312 * | 883,532 |
35–39 | 690,042 | 577,158 | 946,290 * |
40–44 | 840,442 | 1,378,791 | 1,042,774 |
45–49 | 556,424 | 568,619 | 947,753 |
50–54 | 566,088 | 597,174 | 921,355 |
55–59 | 777,936 | −358,210 | −895,647 |
60–64 | 774,095 | 243,716 | 1,054,191 |
65–75 | 123,498 | −151,083 | 1,068,427 |